HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marcus D Flather Selected Research

E 5555

7/2012Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program.
5/2011Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
5/2011Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
11/2010Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marcus D Flather Research Topics

Disease

18Heart Failure
10/2021 - 11/2002
17Myocardial Infarction
05/2014 - 10/2003
12Acute Coronary Syndrome
02/2015 - 10/2003
9Stroke (Strokes)
10/2017 - 08/2005
7Hemorrhage
01/2022 - 09/2007
5Coronary Artery Disease (Coronary Atherosclerosis)
05/2011 - 08/2005
5Unstable Angina
05/2011 - 08/2002
4Coronary Disease (Coronary Heart Disease)
01/2019 - 04/2008
4Cardiovascular Diseases (Cardiovascular Disease)
09/2012 - 04/2006
3Inflammation (Inflammations)
02/2015 - 02/2008
3Atrial Fibrillation
12/2014 - 10/2012
3Thrombosis (Thrombus)
01/2014 - 09/2005
3Type 2 Diabetes Mellitus (MODY)
01/2012 - 04/2008
3Non-ST Elevated Myocardial Infarction
02/2008 - 08/2002
3ST Elevation Myocardial Infarction
07/2004 - 08/2002
2Infarction (Infarctions)
01/2022 - 05/2017
2Marfan Syndrome (Marfan's Syndrome)
05/2015 - 12/2013
2Hypertension (High Blood Pressure)
08/2013 - 07/2004
2Insulin Resistance
01/2012 - 09/2008
2Vascular Diseases (Vascular Disease)
06/2010 - 09/2005
2Peripheral Arterial Disease
05/2007 - 09/2005
2Heart Arrest (Cardiac Arrest)
11/2006 - 10/2003
1Aortic Valve Insufficiency (Aortic Regurgitation)
01/2022
1Aortic Valve Stenosis (Aortic Stenosis)
01/2022
1Tooth Loss
10/2017
1Rupture
05/2017
1Polymyositis
01/2017
1Dermatomyositis (Dermatopolymyositis)
01/2017
1Connective Tissue Diseases (Connective Tissue Disease)
01/2017
1Mixed Connective Tissue Disease (MCTD)
01/2017
1Myositis (Idiopathic Inflammatory Myopathies)
01/2017
1Systemic Scleroderma (Systemic Sclerosis)
01/2017
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2017
1Atherosclerosis
02/2015
1Necrosis
08/2014
1Atherosclerotic Plaque (Atheroma)
05/2014
1Embolism (Embolus)
07/2013
1Ischemia
05/2011
1Anemia
05/2011
1Diabetes Mellitus
07/2010

Drug/Important Bio-Agent (IBA)

8NebivololFDA Link
08/2014 - 11/2002
8CreatinineIBA
01/2012 - 10/2003
7Clopidogrel (Plavix)FDA Link
09/2012 - 09/2005
6Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
06/2010 - 08/2003
5Biomarkers (Surrogate Marker)IBA
10/2017 - 06/2004
4C-Reactive ProteinIBA
01/2019 - 09/2008
4Brain Natriuretic Peptide (Natrecor)FDA Link
01/2019 - 08/2013
4E 5555IBA
07/2012 - 11/2010
3EnzymesIBA
05/2014 - 10/2003
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2012 - 07/2004
3CholesterolIBA
10/2010 - 12/2009
21-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA
10/2017 - 05/2014
2pro-brain natriuretic peptide (1-76)IBA
10/2017 - 08/2014
2CytokinesIBA
05/2017 - 08/2014
2Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
02/2015 - 02/2008
2Nitric Oxide (Nitrogen Monoxide)FDA Link
08/2014 - 02/2011
2Uric Acid (Urate)IBA
08/2014 - 05/2011
2Cytochrome P-450 CYP2C19IBA
09/2012 - 06/2010
2Proteins (Proteins, Gene)FDA Link
01/2012 - 06/2010
2LipidsIBA
01/2012 - 10/2010
2Lipoproteins (Lipoprotein)IBA
01/2012 - 09/2008
2ThrombinFDA Link
05/2011 - 05/2011
2Simvastatin (Zocor)FDA LinkGeneric
06/2010 - 12/2009
2Rosuvastatin Calcium (Crestor)FDA Link
06/2010 - 12/2009
2CalciumIBA
09/2008 - 04/2008
2AlbuminsIBA
09/2008 - 04/2008
2Glycoproteins (Glycoprotein)IBA
08/2003 - 08/2002
1Growth Differentiation Factor 15IBA
10/2017
1Interleukin-6 (Interleukin 6)IBA
10/2017
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2017
1beta-cyclodextrin tetradecasulfate (CTDS)IBA
01/2017
1Ligases (Synthetase)IBA
01/2017
1Rituximab (Mabthera)FDA Link
01/2017
1Angiotensin Receptor AntagonistsIBA
05/2015
1Interleukin-1 (Interleukin 1)IBA
02/2015
1symmetric dimethylarginineIBA
08/2014
1Arginine (L-Arginine)FDA Link
08/2014
1Fas Ligand Protein (Fas Ligand)IBA
08/2014
1Atrial Natriuretic Factor (ANF)IBA
08/2014
1Pharmaceutical PreparationsIBA
08/2014
1Norepinephrine (Noradrenaline)FDA LinkGeneric
08/2014
1CitrullineIBA
08/2014
1Endothelin-1 (Endothelin 1)IBA
08/2014
1Neurotransmitter Agents (Neurotransmitter)IBA
08/2014
1darapladibIBA
05/2014
1Sirolimus (Rapamycin)FDA Link
01/2014
1Fibrillin-1IBA
12/2013
1IrbesartanFDA LinkGeneric
12/2013
1DabigatranFDA Link
07/2013
1Aryldialkylphosphatase (Paraoxonase)IBA
01/2012
1Triglycerides (Triacylglycerol)IBA
01/2012
1ErythropoietinFDA Link
05/2011
1PAR-1 ReceptorIBA
11/2010

Therapy/Procedure

19Therapeutics
10/2021 - 08/2002
5Percutaneous Coronary Intervention
01/2022 - 08/2003
3Secondary Prevention
10/2010 - 12/2009
2Length of Stay
01/2022 - 08/2017
2Patient Readmission
07/2010 - 06/2009
1Transcatheter Aortic Valve Replacement
01/2022
1Stents
01/2014